Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YZ1Q
|
|||
| Drug Name |
RGX-104
|
|||
| Synonyms |
Rgx-104 hydrochloride; RGX-104 hydrochloride; 610318-03-1; UNII-D32013XLTX; SCHEMBL3975944; D32013XLTX; LCMIYQOJZLRHTO-GJFSDDNBSA-N; (r)-2-(3-{3-[[2chloro-3-(trifluoromethyl)benzyl](2,2-diphenylethyl)amino]-3-methyl-propoxy}-phenyl)acetic acid hydrochloride salt
Click to Show/Hide
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 1/2 | [1] | |
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2] | ||
| Company |
Rgenix New York, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C34H34Cl2F3NO3
|
|||
| Canonical SMILES |
CC(CCOC1=CC=CC(=C1)CC(=O)O)N(CC2=C(C(=CC=C2)C(F)(F)F)Cl)CC(C3=CC=CC=C3)C4=CC=CC=C4.Cl
|
|||
| InChI |
1S/C34H33ClF3NO3.ClH/c1-24(18-19-42-29-16-8-10-25(20-29)21-32(40)41)39(22-28-15-9-17-31(33(28)35)34(36,37)38)23-30(26-11-4-2-5-12-26)27-13-6-3-7-14-27;/h2-17,20,24,30H,18-19,21-23H2,1H3,(H,40,41);1H/t24-;/m1./s1
|
|||
| InChIKey |
LCMIYQOJZLRHTO-GJFSDDNBSA-N
|
|||
| CAS Number |
CAS 610318-03-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxysterols receptor LXR (NR1H) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Rgenix. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.